Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients after allo-HSCT: A phase I trial.

Xiaoyu Zhu, Liming Yang, Tianzhong Pan et al.|Journal of Clinical Oncology|2025

Cited by 1